drugset / Trial / NCT05199909
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
Timeline
- Start
- 2022-01-25
- Primary completion
- 2023-12-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 80 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |